Tebentafusp demonstrated a superior overall survival (OS) benefit (hazard ratio [HR] 0.51) compared to investigator’s choice (82% pembrolizumab) in a randomized, Phase 3 trial (IMCgp100-202; N=378) in untreated metastatic uveal melanoma (mUM). The 1-year OS rates for tebentafusp and pembrolizumab were 73% and 59%, respectively. In the single-arm GEM1402 (N=52), the 1-year OS rate for nivolumab plus ipilimumab (N+I) in mUM was 52%. Due to limitations in conducting randomized trials in mUM, we compared OS on tebentafusp or pembrolizumab (IMCgp100-202) to nivolumab plus ipilimumab (GEM1402) in untreated mUM using propensity scoring methods.